The Gross Law Firm Reminds Ultragenyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 6, 2026 – RARE

Core Viewpoint - The Gross Law Firm is notifying shareholders of Ultragenyx Pharmaceutical Inc. regarding a class action lawsuit due to misleading statements about the company's drug setrusumab and its clinical study results [1][3]. Group 1: Allegations and Impact - The allegations state that Ultragenyx provided overly positive statements while concealing material adverse facts about setrusumab's potential and the risks in study protocols [3]. - The Phase III Orbit and Cosmic studies failed to achieve statistical significance in reducing annualized clinical fracture rates compared to placebo or bisphosphonates, contrary to management's claims [3]. - Following the announcement of the study failures on December 29, 2025, Ultragenyx's stock price plummeted from $34.19 to $19.72, a decline of approximately 42.32% in one day [3]. Group 2: Class Action Details - The class period for the lawsuit is from August 3, 2023, to December 26, 2025, and shareholders are encouraged to register for participation [3][4]. - The deadline for shareholders to seek lead plaintiff status is April 6, 2026, and there is no cost to participate in the case [4]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [5].